Modeling and Simulation - PK/PD Archives | Page 33 of 37

Blog Knowledge Base

Why Should You Evaluate Dose Proportionality?

Dose proportionality is a common phrase used pharmacokinetics. Early in the pre-clinical development process, we…

CertaraFebruary 17, 2011

Knowledge Base

What is the Difference Between PK and TK?

Explore the key differences between pharmacokinetics (PK) and toxicokinetics (TK), their roles in drug development,…

CertaraFebruary 15, 2011

Knowledge Base

Why are PK Parameters Lognormally Distributed?

The statistical analysis of pharmacokinetic parameters is often overlooked and not always well understood. The…

CertaraFebruary 10, 2011

Knowledge Base

What are Direct and Indirect Pharmacodynamic Models?

When constructing pharmacodynamic (PD) models, you will often encounter the adjectives “direct” and “indirect” describing…

CertaraFebruary 8, 2011

Knowledge Base

What is Modeling and Simulation?

I am currently attending a short conference on modeling and simulation in pediatric clinical pharmacology,…

CertaraFebruary 1, 2011

Publication

Immediate Consequences of Cigarette Smoking: Rapid Formation of Polycyclic Aromatic Hydrocarbon Diol Epoxides

Polycyclic aromatic hydrocarbons (PAH) are among the likely major causative agents for lung cancer in…

CertaraFebruary 1, 2011

Knowledge Base

Relationship Between AUC and Volume of Distribution

A few days ago on the pharmacokinetics listserve PharmPK, the following question appeared: I’m having…

CertaraJanuary 26, 2011

Blog Knowledge Base

Where Did the 80-125% Bioequivalence Criteria Come From?

Most people involved in clinical pharmacokinetics are familiar with the 80-125% criterion. This criterion is…

CertaraJanuary 24, 2011

Knowledge Base

Generics and Bioequivalence

As the debate about health care in the United States continues forward, the term “generic…

CertaraJanuary 10, 2011

Knowledge Base

What are Compartmental Models?

Learn about compartmental models and their importance in pharmacokinetics. Find out how they simplify drug…

CertaraJanuary 5, 2011

Modeling and Simulation – PK/PD

Why Should You Evaluate Dose Proportionality?

What is the Difference Between PK and TK?

Why are PK Parameters Lognormally Distributed?

What are Direct and Indirect Pharmacodynamic Models?

What is Modeling and Simulation?

Immediate Consequences of Cigarette Smoking: Rapid Formation of Polycyclic Aromatic Hydrocarbon Diol Epoxides

Relationship Between AUC and Volume of Distribution

Where Did the 80-125% Bioequivalence Criteria Come From?

Generics and Bioequivalence

What are Compartmental Models?

Newsletter sign up

Quick links

Solutions

Contact